147 related articles for article (PubMed ID: 37422678)
1. Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma.
Song X; Kelley RK; Green M; Standifer N; Lim K; Zhou D; Dunyak J; Negro A; Kurland JF; Ren S; Khan AA; Gibbs M; Abou-Alfa GK
Clin Pharmacol Ther; 2023 Oct; 114(4):874-882. PubMed ID: 37422678
[TBL] [Abstract][Full Text] [Related]
2. Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma.
Song X; Kelley RK; Khan AA; Standifer N; Zhou D; Lim K; Krishna R; Liu L; Wang K; McCoon P; Negro A; He P; Gibbs M; Kurland JF; Abou-Alfa GK
Clin Cancer Res; 2023 Feb; 29(4):754-763. PubMed ID: 36477555
[TBL] [Abstract][Full Text] [Related]
3. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
France NL; Blair HA
Target Oncol; 2024 Jan; 19(1):115-123. PubMed ID: 38236364
[TBL] [Abstract][Full Text] [Related]
4. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B; Chan SL; Kelley RK; Lau G; Kudo M; Sukeepaisarnjaroen W; Yarchoan M; De Toni EN; Furuse J; Kang YK; Galle PR; Rimassa L; Heurgué A; Tam VC; Van Dao T; Thungappa SC; Breder V; Ostapenko Y; Reig M; Makowsky M; Paskow MJ; Gupta C; Kurland JF; Negro A; Abou-Alfa GK;
Ann Oncol; 2024 May; 35(5):448-457. PubMed ID: 38382875
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Exposure-Response Analysis of Tremelimumab 300 mg Single Dose Combined with Durvalumab 1500 mg Q4W (STRIDE) in Patients with Unresectable Hepatocellular Carcinoma.
Lim K; Abegesah A; Fan C; He JZ; Song X; Chen C; Negro A; Makowsky M; Gupta C; Ren S; Phipps A; Gibbs M; Zhou D
J Clin Pharmacol; 2023 Nov; 63(11):1221-1231. PubMed ID: 37300457
[TBL] [Abstract][Full Text] [Related]
6. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Kelley RK; Sangro B; Harris W; Ikeda M; Okusaka T; Kang YK; Qin S; Tai DW; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; Bendell J; Kim TY; Standifer N; He P; Makowsky M; Negro A; Kudo M; Abou-Alfa GK
J Clin Oncol; 2021 Sep; 39(27):2991-3001. PubMed ID: 34292792
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
[TBL] [Abstract][Full Text] [Related]
8. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
9. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
10. Tremelimumab: First Approval.
Keam SJ
Drugs; 2023 Jan; 83(1):93-102. PubMed ID: 36571670
[TBL] [Abstract][Full Text] [Related]
11. FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.
Patel TH; Brewer JR; Fan J; Cheng J; Shen YL; Xiang Y; Zhao H; Lemery SJ; Pazdur R; Kluetz PG; Fashoyin-Aje LA
Clin Cancer Res; 2024 Jan; 30(2):269-273. PubMed ID: 37676259
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ferris RL; Haddad R; Even C; Tahara M; Dvorkin M; Ciuleanu TE; Clement PM; Mesia R; Kutukova S; Zholudeva L; Daste A; Caballero-Daroqui J; Keam B; Vynnychenko I; Lafond C; Shetty J; Mann H; Fan J; Wildsmith S; Morsli N; Fayette J; Licitra L
Ann Oncol; 2020 Jul; 31(7):942-950. PubMed ID: 32294530
[TBL] [Abstract][Full Text] [Related]
14. Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
Goldman JW; Piha-Paul SA; Curti B; Pedersen KS; Bauer TM; Groenland SL; Carvajal RD; Chhaya V; Kirby G; McGlinchey K; Hammond SA; Streicher K; Townsley DM; Chae YK; Voortman J; Marabelle A; Powderly J
Clin Cancer Res; 2022 Sep; 28(17):3709-3719. PubMed ID: 35699623
[TBL] [Abstract][Full Text] [Related]
15. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.
Agdashian D; ElGindi M; Xie C; Sandhu M; Pratt D; Kleiner DE; Figg WD; Rytlewski JA; Sanders C; Yusko EC; Wood B; Venzon D; Brar G; Duffy AG; Greten TF; Korangy F
Cancer Immunol Immunother; 2019 Apr; 68(4):599-608. PubMed ID: 30688989
[TBL] [Abstract][Full Text] [Related]
16. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer).
Abou-Alfa GK; Lau G; Kudo M; Chan SL; Kelley RK; Furuse J; Sukeepaisarnjaroen W; Kang YK; Dao TV; De Toni EN; Rimassa L; Breder V; Vasilyev A; Heurgué A; Tam VC; Mody K; Thungappa SC; Ostapenko Y; Yau T; Azevedo S; Varela M; Cheng AL; Qin S; Galle PR; Ali S; Gupta C; Makowsky M; Kurland JF; Negro A; Sangro B
Future Oncol; 2023 Dec; 19(38):2505-2516. PubMed ID: 37671641
[TBL] [Abstract][Full Text] [Related]
17. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8
Ferrarotto R; Bell D; Rubin ML; Hutcheson KA; Johnson JM; Goepfert RP; Phan J; Elamin YY; Torman DK; Warneke CL; Hessel AC; Garden AS; Myers JN; Johnson FM; Lee JJ; Sikora AG; Gillison ML; Glisson BS; Gross ND
Clin Cancer Res; 2020 Jul; 26(13):3211-3219. PubMed ID: 32269052
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
Monge C; Xie C; Myojin Y; Coffman K; Hrones DM; Wang S; Hernandez JM; Wood BJ; Levy EB; Juburi I; Hewitt SM; Kleiner DE; Steinberg SM; Figg WD; Redd B; Homan P; Cam M; Ruf B; Duffy AG; Greten TF
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36754451
[TBL] [Abstract][Full Text] [Related]
19. Immuno-Oncology in Hepatocellular Carcinoma: 2017 Update.
Kudo M
Oncology; 2017; 93 Suppl 1():147-159. PubMed ID: 29258079
[TBL] [Abstract][Full Text] [Related]
20. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.
Maestri M; Pallozzi M; Santopaolo F; Cerrito L; Pompili M; Gasbarrini A; Ponziani FR
Expert Opin Investig Drugs; 2022 Apr; 31(4):347-360. PubMed ID: 35072571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]